CD274 and hepatocellular carcinoma: In summary, our study shows that ipilimumab and nivolumab can have meaningful antitumoral activity in a relevant proportion of patients with advanced HCC after the failure of prior PD-1/PD-L1 inhibitor-based combinations like atezolizumab and bevacizumab.